Last checked at 23 May 2017 14:03
Oxford BioMedica Annual General Meeting
London, UK - 23 May 2017: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, announces today that all resolutions proposed were duly passed at its Annual General Meeting (AGM), held today in London.
In accordance with Listing Rule 9.6.18 the following resolutions are those which were passed at the meeting concerning special business:
· Resolution 7: to authorise the Directors to allot equity securities for cash, pursuant to section 570 of the Companies Act 2006 as if section 561 of the Companies Act 2006 did not apply to such allotment, up to an aggregate nominal amount of 5 per cent. of the presently issued shares;
· Resolution 8: to empower the Directors to allot equity securities for cash, pursuant to section 570 of the Companies Act 2006 as if section 561 of the Companies Act 2006 did not apply to such allotment, up to an aggregate nominal amount of 5 per cent. of the presently issued shares in connection with an acquisition or specified capital investment; and
· Resolution 9: to permit the Directors to convene general meetings (other than annual general meetings) on not less than 14 days' notice.
The full text of all the resolutions can be viewed in the Notice of Meeting by visiting the Group's website at www.oxfordbiomedica.co.uk.
Certified copies of the document setting out the above resolutions passed at the 2017 AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at: http://www.morningstar.co.uk/uk/NSM.
The results of the proxy voting in advance of the meeting are shown below. On the Record Date (19 May 2017) there were 3,088,326,065 1p ordinary shares in issue, each carrying one vote per share.
Resolution |
Votes For | Votes at Chairman's Discretion | Votes at other proxy Discretion |
Votes Against |
Votes Withheld |
Total votes cast | Result |
Ordinary resolutions | |||||||
1 | 1,888,465,188 | 802,799 | 6,958,793 | 604,970 | 398,641 | 1,897,230,391 | Passed |
2 | 1,601,919,465 | 928,694 | 6,958,793 | 4,701,911 | 282,721,528 | 1,897,230,391 | Passed |
3 | 1,880,264,095 | 868,254 | 6,958,793 | 1,126,450 | 8,012,799 | 1,897,230,391 | Passed |
4 |
1,880,712,558 |
872,425 |
6,958,793 |
664,300 |
8,022,315 |
1,897,230,391 |
Passed |
5 | 1,813,674,842 | 880,635 | 6,958,793 | 75,322,036 | 394,085 | 1,897,230,391 | Passed |
6 | 1,887,924,882 | 925,661 | 6,958,793 | 857,070 | 563,985 | 1,897,230,391 | Passed |
Special resolutions |
| ||||||
7 | 1,774,042,262 | 1,002,090 | 6,958,793 | 1,619,809 | 113,607,437 | 1,897,230,391 | Passed |
8 | 1,887,104,129 | 1,002,090 | 6,958,793 | 1,557,942 | 607,437 | 1,897,230,391 | Passed |
9 | 1,879,803,796 | 1,001,125 | 6,958,793 | 9,042,530 | 424,147 | 1,897,230,391 | Passed |
- Ends -
For further information, please contact: |
|
Oxford BioMedica plc: John Dawson, Chief Executive Officer Tim Watts, Chief Financial Officer |
Tel: +44 (0)1865 783 000 |
Consilium Strategic Communications Mary-Jane Elliott/Matthew Neal/Chris Welsh/Laura Thornton
|
Tel: +44 (0)20 3709 5700 |
Notes for editors
About Oxford BioMedica®
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy company focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®) through which the Group develops in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 250 people. Further information is available at www.oxfordbiomedica.co.uk.